Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

Wiley - 2019
Jingbo Wang1,2, Xue F. Huang2,1, Furong Li2,1
1Shenzhen Cell Therapy Public Service Platform Shenzhen 218020 Guangdong P. R. China
2Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College, Shenzhen People's Hospital Jinan University 1017 Dongmen Road North Shenzhen 518020 Guangdong P. R. China

Tóm tắt

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. Dendritic cells (DCs) are the key factors providing protective immunity against lung tumors and clinical trials have proven that DC function is reduced in lung cancer patients. It is evident that the immunoregulatory network may play a key role in the failure of the immune response to terminate tumors. Lung tumors likely employ numerous strategies to suppress DC‐based anti‐tumor immunity. Here, we summarize the recent advances in our understanding on lung tumor‐induced immunosuppression in DCs, which affects the initiation and development of T‐cell responses. We also describe which existing measures to restore DC function may be useful for clinical treatment of lung tumors. Furthering our knowledge of how lung cancer cells alter DC function to generate a tumor‐supportive environment will be essential in order to guide the design of new immunotherapy strategies for clinical use.

Từ khóa


Tài liệu tham khảo

10.1007/s11684‐019‐0683‐y

10.21037/tlcr.2017.03.01

10.4103/0019‐509X.219579

10.1016/j.lungcan.2017.07.023

10.1245/s10434‐012‐2431‐2

10.1158/1078‐0432.CCR‐17‐1341

10.1371/journal.pone.0171539

10.1016/j.jtho.2018.01.012

10.1016/j.trsl.2017.04.004

Hersom M, 2018, Companion and complementary diagnostics‐focus on PD‐L1 expression assays for PD‐1/PD‐L1 checkpoint inhibitors in non‐small cell lung cancer, Ther Drug Monit, 40, 9, 10.1097/FTD.0000000000000460

10.1007/s40291‐017‐0308‐6

10.1186/s40425‐018‐0349‐3

Gonzalez‐Cao M, 2015, Targeting PD‐1/PD‐L1 in lung cancer: current perspectives, Lung Cancer (Auckl), 6, 55

10.1186/s40880‐019‐0376‐6

10.1080/2162402X.2015.1085146

10.3892/mmr.2013.1738

Fatima F, 2015, Stem cell‐derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy, Chin J Cancer, 34, 541

10.1080/2162402X.2015.1071008

10.1016/j.chest.2016.09.030

10.4110/in.2016.16.1.75

10.1007/s00262‐017‐1958‐2

Shang N, 2017, Dendritic cells based immunotherapy, Am J Cancer Res., 7, 2091

10.1097/JTO.0b013e31821c421d

10.1016/j.cellimm.2017.12.006

10.1007/s00262‐018‐2143‐y

10.1158/0008‐5472.CAN‐13‐3118

10.3389/fphys.2018.00288

10.1186/1471‐2172‐14‐5

10.1111/j.0105‐2896.2009.00879.x

10.1189/jlb.0610329

10.1016/j.immuni.2017.12.014

10.1007/s12032‐008‐9142‐3

10.1016/S0065‐2776(06)93007‐7

10.1016/j.immuni.2015.04.020

10.1038/ni.3197

10.1038/s41467‐018‐08271‐x

10.1007/s00262‐006‐0215‐x

10.1016/j.cell.2017.04.014

10.4049/jimmunol.177.11.7784

10.1165/rcmb.2006‐0284OC

10.4049/jimmunol.182.2.963

10.1111/ajt.14648

10.1016/j.semcdb.2017.12.009

10.1038/cmi.2014.130

10.1016/j.ccell.2016.06.003

10.1016/j.immuni.2016.03.012

10.1080/2162402X.2016.1253655

10.1016/j.cellimm.2014.08.006

10.1016/j.semcdb.2018.02.014

10.1038/s41590‐018‐0143‐x

10.1007/s00262‐011‐1057‐8

10.1158/0008‐5472.CAN‐12‐2271

10.1080/2162402X.2015.1008355

10.3389/fimmu.2017.01622

Liu C, 2008, Plasmacytoid dendritic cells induce NK cell‐dependent, tumor antigen‐specific T cell cross‐priming and tumor regression in mice, J Clin Invest, 118, 1165

10.4049/jimmunol.1000881

10.1158/2326‐6066.CIR‐13‐0143

10.4049/jimmunol.1202086

10.1007/s13277‐013‐1297‐7

10.1016/j.ajpath.2015.07.009

10.1002/ijc.28590

10.4049/jimmunol.1403161

Zhang C, 2017, The effect of semimature dendritic cell and the levels of Treg on transplantation tolerance of hepatocytes differentiated from mouse embryonic stem cell, Zhonghua Yi Xue Za Zhi, 97, 259

10.4161/21624011.2014.955331

10.4049/jimmunol.1400725

10.1007/s00262‐016‐1820‐y

10.1158/0008‐5472.CAN‐13‐1342

10.1158/0008‐5472.CAN‐17‐1307

10.1038/srep45395

10.1016/j.vaccine.2017.06.041

10.1158/2159‐8290.CD‐11‐0073

10.1016/j.celrep.2016.05.085

10.1053/j.semtcvs.2016.02.008

10.1016/j.bbrc.2016.12.021

10.1159/000453175

10.1016/j.lungcan.2009.01.017

10.3390/ncrna3010010

10.1002/ijc.28945

10.1016/j.bbrc.2017.07.144

10.1038/ni.2376

10.1016/j.clim.2008.09.014

10.3892/mmr.2014.2573

10.4049/jimmunol.1002940

10.1016/j.semcancer.2011.12.004

10.4161/21624011.2014.955684

10.1016/j.cyto.2011.01.008

Niki M, 2017, New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non‐small‐cell lung cancer, Lung Cancer (Auckl), 8, 91

10.5301/tj.5000656

10.1097/PAI.0b013e3182849808

10.1007/s00005‐012‐0183‐0

10.1007/s00262‐017‐2087‐7

10.1016/j.imlet.2018.05.002

10.1038/nm0398‐328

10.3389/fimmu.2018.00982

10.1080/2162402X.2018.1445457

10.1016/j.vaccine.2018.06.016

10.1155/2018/5708239

Obleukhova I, 2018, Use of antigen‐primed dendritic cells for inducing antitumor immune responses in vitro in patients with non‐small cell lung cancer, Oncol Lett, 15, 1297

10.1016/j.intimp.2017.09.014

Geskin LJ, 2018, Three antigen‐loading methods in dendritic cell vaccines for metastatic melanoma, Melanoma Res., 28, 211, 10.1097/CMR.0000000000000441

10.15171/bi.2019.08

10.1080/2162402X.2017.1319044

10.1016/j.tranon.2016.12.002

10.1016/j.ijpharm.2019.05.039

10.1155/2018/9845123

10.1016/j.vaccine.2007.11.020

10.1186/s12885‐017‐3859‐3

10.1158/1078‐0432.CCR‐16‐2821

10.1615/CritRevImmunol.v18.i1‐2.110

Chakravarty PK, 1999, Flt3‐ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer, Cancer Res., 59, 6028

10.1038/cgt.2017.21

10.1038/s41563‐018‐0028‐2

SomaiahN et al.First‐in‐class first‐in‐human study evaluating LV305 a dendritic‐cell tropic lentiviral vector in sarcoma and other solid tumors expressing NY‐ESO‐1.Clin Cancer Res.2019;10.1158/1078‐0432.CCR‐19‐102531227504

10.1007/s00262‐018‐2287‐9

10.3389/fimmu.2018.00206

10.1186/1756‐9966‐31‐3

10.1016/S1567‐5769(02)00251‐5

10.1080/2162402X.2017.1417721

10.1016/j.canlet.2013.03.010